Ariad Pharmaceuticals (ARIA) 5.89 $ARIA
INNATE PHARMA APPOINTS PIERRE DODION AS CHIEF MEDICAL OFFICER AND MEMBER OF THE EXECUTIVE COMMITTEE
GlobeNewswire - Tue Sep 16, 11:40AM CDT
-- Marcel Rozencweig becomes President of Innate Pharma Inc., based in the US
Why Ariad Pharmaceuticals, Inc. Stock Plunged 11% in 2014
Sean Williams, The Motley Fool - Motley Fool - Mon Sep 08, 1:10PM CDT
All things considered, it's been a relatively calm year for Ariad Pharmaceuticals shareholders after their stock went cliff-diving in October of last year. With its shares down 11% year-to-date stakeholders probably aren't happy, but compared to...
Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte
at The Street - Fri Sep 05, 7:55AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen
PR Newswire - Thu Sep 04, 7:55AM CDT
On Wednesday, September 03, 2014, the NASDAQ Composite ended at 4,572.57, down 0.56%, the Dow Jones Industrial Average finished the day 0.06% higher at 17,078.28, and the S&P 500 closed at 2,000.72, down 0.08%. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 740.75, up 0.41%, with the index advancing 6.93% in the previous three months. Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Arrowhead Research Corporation (NASDAQ: ARWR), Celgene Corporation (NASDAQ: CELG), and Amgen Inc. (NASDAQ: AMGN). Free research on these five companies can be accessed at:
'Mad Money' Lightning Round: Yahoo! Is One of the Best Buys Around
at The Street - Thu Sep 04, 5:00AM CDT
Cramer likes Araid Pharmaceuticals and Occidental Petroleum and is sticking with his Taser recommendation.
Jim Cramer's 'Mad Money' Recap: These Are 3 Stocks Cramer Trusts
at The Street - Wed Sep 03, 7:17PM CDT
Cramer wants Apple, Microsoft and Dow Chemical on his team.
Ariad Pharmaceuticals Rises 4.50% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Aug 26, 4:26PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $6.12 to a high of $6.65. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of $6.25 on volume of 14.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Ariad Pharmaceuticals (ARIA) Stock Is Up Today
at The Street - Tue Aug 26, 11:36AM CDT
Ariad Pharmaceuticals (ARIA) rose Tuesday as Roche's $8.3 billion acquisition of InterMune (ITMN) has led the biotech sector higher.
5 Stocks Insiders Love Right Now
at The Street - Thu Aug 21, 1:11PM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
Look for Shares of Ariad Pharmaceuticals to Potentially Pullback after Yesterday's 2.90% Rise
Comtex SmarTrend(R) - Tue Aug 12, 5:00PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $5.48 to a high of $5.79. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $5.63 on volume of 5.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIAD Falls on Wider-than-Expected Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 11:21AM CDT
ARIAD (ARIA) reported a loss of 30 cents per share in the second quarter of 2014, wider than the Zacks Consensus Estimate of a loss of 27 cents.
11.6% Return Seen to Date on SmarTrend Ariad Pharmaceuticals Call (ARIA)
Comtex SmarTrend(R) - Fri Aug 08, 10:00AM CDT
SmarTrend identified a Downtrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 8th, 2014 at $6.07. In approximately 1 month, Ariad Pharmaceuticals has returned 11.62% as of today's recent price of $5.36.
ARIAD Reports Second Quarter 2014 Financial Results and Development Progress
Business Wire - Wed Aug 06, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the second quarter of 2014, including revenue from sales of Iclusig(R) (ponatinib). The Company also provided an update on corporate developments.
Will GW Pharmaceuticals (GWPH) Miss this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 3:45PM CDT
GW Pharmaceuticals (GWPH) is scheduled to report third-quarter fiscal 2014 results on Aug 6.
Should You Sell Ariad Pharmaceuticals (ARIA) Before Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 7:48AM CDT
Ariad Pharmaceuticals (ARIA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. The company looks set to produce a positive earnings surprise and outperform the market.
ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Israel
Business Wire - Tue Aug 05, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medison Pharma Ltd, Israel's leading international marketing group for innovative pharmaceuticals, today announced that ARIAD has granted Medison exclusive rights to commercialize Iclusig(R) (ponatinib) in Israel in patients with Philadelphia-positive (Ph+) leukemias.
The Zacks Analyst Blog Highlights: AbbVie, Shire, ARIAD Pharmaceuticals, ImmunoGen and Durata Therapeutics
PR Newswire - Fri Aug 01, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie Inc. (NYSE:ABBV-Free Report), Shire (Nasdaq:SHPG-Free Report), ARIAD Pharmaceuticals, Inc. (Nasdaq:ARIA-Free Report), ImmunoGen, Inc. (Nasdaq:IMGN-Free Report) and Durata Therapeutics, Inc. (Nasdaq
RTX-Free Report).
Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma
PR Newswire - Fri Aug 01, 8:00AM CDT
On Thursday, July 31, 2014, the NASDAQ Composite ended at 4,369.77, down 2.09%, the Dow Jones Industrial Average finished the day 1.88% lower at 16,563.30, and the S&P 500 closed at 1,930.67, down 2.00%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 704.37, down 2.03%, and the index has declined 0.02% in the last one month. Investor-Edge has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Galena Biopharma Inc. (NASDAQ: GALE), Geron Corporation(NASDAQ: GERN), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research on these five companies can be accessed at:
3 Eye-Catching Health Care Stocks this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:44AM CDT
These stocks are well positioned in today’s market environment.
3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Jul 30, 5:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
INNATE PHARMA APPOINTS PIERRE DODION AS CHIEF MEDICAL OFFICER AND MEMBER OF THE EXECUTIVE COMMITTEE
GlobeNewswire - Tue Sep 16, 11:40AM CDT
-- Marcel Rozencweig becomes President of Innate Pharma Inc., based in the US
Why Ariad Pharmaceuticals, Inc. Stock Plunged 11% in 2014
Sean Williams, The Motley Fool - Motley Fool - Mon Sep 08, 1:10PM CDT
All things considered, it's been a relatively calm year for Ariad Pharmaceuticals shareholders after their stock went cliff-diving in October of last year. With its shares down 11% year-to-date stakeholders probably aren't happy, but compared to...
Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte
at The Street - Fri Sep 05, 7:55AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen
PR Newswire - Thu Sep 04, 7:55AM CDT
On Wednesday, September 03, 2014, the NASDAQ Composite ended at 4,572.57, down 0.56%, the Dow Jones Industrial Average finished the day 0.06% higher at 17,078.28, and the S&P 500 closed at 2,000.72, down 0.08%. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 740.75, up 0.41%, with the index advancing 6.93% in the previous three months. Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Arrowhead Research Corporation (NASDAQ: ARWR), Celgene Corporation (NASDAQ: CELG), and Amgen Inc. (NASDAQ: AMGN). Free research on these five companies can be accessed at:
'Mad Money' Lightning Round: Yahoo! Is One of the Best Buys Around
at The Street - Thu Sep 04, 5:00AM CDT
Cramer likes Araid Pharmaceuticals and Occidental Petroleum and is sticking with his Taser recommendation.
Jim Cramer's 'Mad Money' Recap: These Are 3 Stocks Cramer Trusts
at The Street - Wed Sep 03, 7:17PM CDT
Cramer wants Apple, Microsoft and Dow Chemical on his team.
Ariad Pharmaceuticals Rises 4.50% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Aug 26, 4:26PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $6.12 to a high of $6.65. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of $6.25 on volume of 14.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Ariad Pharmaceuticals (ARIA) Stock Is Up Today
at The Street - Tue Aug 26, 11:36AM CDT
Ariad Pharmaceuticals (ARIA) rose Tuesday as Roche's $8.3 billion acquisition of InterMune (ITMN) has led the biotech sector higher.
5 Stocks Insiders Love Right Now
at The Street - Thu Aug 21, 1:11PM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
Look for Shares of Ariad Pharmaceuticals to Potentially Pullback after Yesterday's 2.90% Rise
Comtex SmarTrend(R) - Tue Aug 12, 5:00PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $5.48 to a high of $5.79. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $5.63 on volume of 5.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIAD Falls on Wider-than-Expected Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 11:21AM CDT
ARIAD (ARIA) reported a loss of 30 cents per share in the second quarter of 2014, wider than the Zacks Consensus Estimate of a loss of 27 cents.
11.6% Return Seen to Date on SmarTrend Ariad Pharmaceuticals Call (ARIA)
Comtex SmarTrend(R) - Fri Aug 08, 10:00AM CDT
SmarTrend identified a Downtrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 8th, 2014 at $6.07. In approximately 1 month, Ariad Pharmaceuticals has returned 11.62% as of today's recent price of $5.36.
ARIAD Reports Second Quarter 2014 Financial Results and Development Progress
Business Wire - Wed Aug 06, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the second quarter of 2014, including revenue from sales of Iclusig(R) (ponatinib). The Company also provided an update on corporate developments.
Will GW Pharmaceuticals (GWPH) Miss this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 3:45PM CDT
GW Pharmaceuticals (GWPH) is scheduled to report third-quarter fiscal 2014 results on Aug 6.
Should You Sell Ariad Pharmaceuticals (ARIA) Before Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 7:48AM CDT
Ariad Pharmaceuticals (ARIA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. The company looks set to produce a positive earnings surprise and outperform the market.
ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Israel
Business Wire - Tue Aug 05, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medison Pharma Ltd, Israel's leading international marketing group for innovative pharmaceuticals, today announced that ARIAD has granted Medison exclusive rights to commercialize Iclusig(R) (ponatinib) in Israel in patients with Philadelphia-positive (Ph+) leukemias.
The Zacks Analyst Blog Highlights: AbbVie, Shire, ARIAD Pharmaceuticals, ImmunoGen and Durata Therapeutics
PR Newswire - Fri Aug 01, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie Inc. (NYSE:ABBV-Free Report), Shire (Nasdaq:SHPG-Free Report), ARIAD Pharmaceuticals, Inc. (Nasdaq:ARIA-Free Report), ImmunoGen, Inc. (Nasdaq:IMGN-Free Report) and Durata Therapeutics, Inc. (Nasdaq
RTX-Free Report). Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma
PR Newswire - Fri Aug 01, 8:00AM CDT
On Thursday, July 31, 2014, the NASDAQ Composite ended at 4,369.77, down 2.09%, the Dow Jones Industrial Average finished the day 1.88% lower at 16,563.30, and the S&P 500 closed at 1,930.67, down 2.00%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 704.37, down 2.03%, and the index has declined 0.02% in the last one month. Investor-Edge has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Galena Biopharma Inc. (NASDAQ: GALE), Geron Corporation(NASDAQ: GERN), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research on these five companies can be accessed at:
3 Eye-Catching Health Care Stocks this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:44AM CDT
These stocks are well positioned in today’s market environment.
3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Jul 30, 5:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
